<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shroff R</submitter><funding>Kidney Research UK</funding><funding>National Institute for Health Research (NIHR)</funding><funding>NIH</funding><pagination>1098-1113</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5837199</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(7)</volume><pubmed_abstract>Vitamin D deficiency is widely prevalent and often severe in children and adults with chronic kidney disease (CKD). Although native vitamin D {25-hydroxyvitamin D [25(OH)D]} is thought to have pleiotropic effects on many organ systems, its skeletal effects have been most widely studied. The 25(OH)D deficiency is causally linked with rickets and fractures in healthy children and those with CKD, contributing to the CKD-mineral and bone disorder (MBD) complex. There are few studies to provide evidence for vitamin D therapy or guidelines for its use in CKD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs have developed recommendations for the evaluation, treatment and prevention of vitamin D deficiency in children with CKD. We present</pubmed_abstract><journal>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</journal><pubmed_title>Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.</pubmed_title><pmcid>PMC5837199</pmcid><funding_grant_id>RP39/2013</funding_grant_id><funding_grant_id>CDF-2016-09-038</funding_grant_id><funding_grant_id>KKR/Paed2017/01</funding_grant_id><funding_grant_id>ICA-CDRF-2016-02-057</funding_grant_id><pubmed_authors>Bacchetta J</pubmed_authors><pubmed_authors>Bakkaloglu S</pubmed_authors><pubmed_authors>Stefanidis CJ</pubmed_authors><pubmed_authors>Wan M</pubmed_authors><pubmed_authors>Klaus G</pubmed_authors><pubmed_authors>Bishop N</pubmed_authors><pubmed_authors>Fischer DC</pubmed_authors><pubmed_authors>Nagler EV</pubmed_authors><pubmed_authors>Edefonti A</pubmed_authors><pubmed_authors>Schmitt CP</pubmed_authors><pubmed_authors>Cozzolino M</pubmed_authors><pubmed_authors>European Society for Paediatric Nephrology Chronic                    Kidney Disease Mineral and Bone Disorders and Dialysis Working                    Groups</pubmed_authors><pubmed_authors>Shroff R</pubmed_authors><pubmed_authors>Haffner D</pubmed_authors><pubmed_authors>Vande Walle J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.</name><description>Vitamin D deficiency is widely prevalent and often severe in children and adults with chronic kidney disease (CKD). Although native vitamin D {25-hydroxyvitamin D [25(OH)D]} is thought to have pleiotropic effects on many organ systems, its skeletal effects have been most widely studied. The 25(OH)D deficiency is causally linked with rickets and fractures in healthy children and those with CKD, contributing to the CKD-mineral and bone disorder (MBD) complex. There are few studies to provide evidence for vitamin D therapy or guidelines for its use in CKD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs have developed recommendations for the evaluation, treatment and prevention of vitamin D deficiency in children with CKD. We present</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jul</publication><modification>2025-04-06T23:39:02.804Z</modification><creation>2019-03-26T23:43:20Z</creation></dates><accession>S-EPMC5837199</accession><cross_references><pubmed>28873969</pubmed><doi>10.1093/ndt/gfx065</doi></cross_references></HashMap>